Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

• Status: Completed
• Trial end date: 2017-08-25
• Target enrollment: 0
• Participant gender: All

Summary

this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taro Pharmaceuticals USA

Criteria

Inclusion Criteria:

• Patients with a definite clinical diagnosis of stable atopic dermatitis

Exclusion Criteria:

• Patient is under the age of 2